title: [Disease-Modifying Therapy for Parkinson's Disease].
abstract: Currently, treatment of Parkinson's disease aims at alleviating its symptoms. However development of disease-modifying drugs has been a remarkable advancement in recent years. Furthermore, clinical trials of immunotherapy against α-synuclein, a protein involved in the pathogenesis of and lesion expansion in Parkinson's disease, have been initiated. Here, the disease-modifying treatment for patients with Parkinson's disease including the current α-synuclein immunotherapy, gene therapy, protein injection therapy, and cell transplantation therapy, has been reviewed.
authors.affiliation: Department of Neurology, Juntendo University Urayasu Hospital.
authors.forename: Hideki
authors.initials: H
authors.lastname: Shimura
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Hattori
mesh_terms: D001921:Brain / Q000473:pathology*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D010300:Parkinson Disease / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D051844:alpha-Synuclein / Q000378:metabolism*
chemical_list: D051844:alpha-Synuclein